Hancock Jaffe Laboratories will fund a pivotal trial of its VenoValve device to treat lower limb chronic deep venous insufficiency with $41.4m raised in a new public stock offering completed on 11 February.
The company sold nearly 6 million shares of common stock and warrants to purchase nearly 3 million common shares, exceeding its original expectations for the offering. On 9 February, the company announced it planned to raise about $36m by selling about 5
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?